Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DIVE INTO DIALYSIS: NxStage Aims To Transform Home Hemodialysis Into $2bn Market

This article was originally published in Clinica

Executive Summary

For the second part of Clinica’s three-part special series on the dialysis market, Reed Miller talked to the CEO of NxStage Medical, a Massachusetts-based company that markets the NxStage System One, which the firm touts as the only “truly portable” hemodialysis system FDA-cleared for home hemodialysis and home nocturnal hemodialysis. As the company is set to face competition for home hemodialysis customers from upstarts like Quanta, profiled in part 1 of this series, and giants like Fresenius Medical Care, the subject of part 3, NxStage is planning to use home hemodialysis as a “beachhead” to invade other, more lucrative markets


Related Content

Quanta Prepares For Launch Of SC+ Personal Dialysis Machine
Market Intel: Holding Out For Home Hemodialysis: Still-Modest Market Promises Bigger Growth
Fresenius Homes In On NxStage





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts